Showing results (1391-1400 of 1,423) with videos related to

Sort By:
Pageof 143
Journal of Child Neurology|March 21, 2012
Consensus statement on standard of care for congenital myopathiesChing H Wang, James J Dowling, Kathryn North, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2016
Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast CancerHeather A Parsons, Julia A Beaver, Ashley Cimino-Mathews, et al.
Muscle & Nerve|July 22, 2014
Ataluren treatment of patients with nonsense mutation dystrophinopathyKatharine Bushby, Richard Finkel, Brenda Wong, et al.
Journal of Medicinal Chemistry|June 11, 2008
Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonistWilliam D Shipe, James C Barrow, Zhi-Qiang Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2019
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain MetastasesRachel A Freedman, Rebecca S Gelman, Carey K Anders, et al.
Neurology|January 23, 2015
Novel mutations expand the clinical spectrum of DYNC1H1-associated spinal muscular atrophyMariacristina Scoto, Alexander M Rossor, Matthew B Harms, et al.
Nature Communications|September 7, 2019
The future of Blue Carbon sciencePeter I Macreadie, Andrea Anton, John A Raven, et al.
Journal of Medicinal Chemistry|September 27, 2008
Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channelsZhi-Qiang Yang, James C Barrow, William D Shipe, et al.
Nature Communications|November 10, 2019
Author Correction: The future of Blue Carbon sciencePeter I Macreadie, Andrea Anton, John A Raven, et al.
Pageof 143